Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease
NCT00134251
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
INDUSTRY
Sponsor class
Conditions
Parkinson's Disease
Interventions
DRUG:
SLV308
Sponsor
Solvay Pharmaceuticals